News Releases

KromaTiD Inc. to Present at the 2019 Biotech Showcase in San Francisco

FORT COLLINS, Colo., Jan. 3, 2019 /PRNewswire/ -- KromaTiD, Inc. announced today that it has been selected to present at the 2019 Biotech Showcase and investor conference. David P. Sebesta, KromaTiD's Chief Commercial Officer, will provide a business and technology update. Applications of directional Genomic Hybridization (dGH) for single-cell analysis of structural genomic misrepair associated with gene editing methods such as CRISPR-Cas9 will be the focus. The conference will be held January 7-9 in San Francisco, and KromaTiD will be presenting at the Hilton San Francisco Union Square on Monday, January 7, 2019 at 4:30 p.m. PST.

About Biotech Showcase:

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and the life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during the bellwether week which sets the tone for the coming year. Now in its eleventh year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-on-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group.

About Directional Genomic Hybridization (dGH™):

 dGH™ is a structural genomics platform uniquely capable of de novo discovery, detection and quantitation of random, low frequency and complex structural variations.

About KromaTiD

Based in Fort Collins Colorado, KromaTiD offers a full suite of dGH™ and Pinpoint FISH™ structural genomic solutions, including custom products and services.  KromaTiD is seeking strategic partners to accelerate the development of its high throughput, automated, whole genome platform to enable widespread adoption of their powerful approach to structural genomics for a variety of applications, including gene editing, undiagnosed diseases screening and oncology.

David Sebesta
Chief Commercial Officer

SOURCE KromaTiD Inc.